21 results
8-K
EX-99.1
KPTI
Karyopharm Therapeutics Inc
3 Nov 22
Karyopharm Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
4:11pm
Third Quarter 2021–
– Initiated Phase 3 Study Evaluating Selinexor as a Maintenance Therapy in Women with Advanced or Recurrent TP53 Wild-Type … of the pivotal Phase 3 study evaluating selinexor as a maintenance therapy in women with TP53 wild-type endometrial cancer and anticipate sharing topline
8-K
EX-99.2
KPTI
Karyopharm Therapeutics Inc
8 Feb 22
Karyopharm Reports Strong Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress
8:16am
that can give them more time with their friends and families.”
“Women with advanced or recurrent endometrial cancer face a poor prognosis,” explains Dr
8-K
EX-99.1
f7e 1uhbuik
18 Dec 20
Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
11:58am
8-K
EX-99.2
l701h71zs0u1x1donxy
2 Nov 20
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
4:11pm
8-K
EX-99.1
pihh0g7 tzfnj
2 Nov 20
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
4:11pm
8-K
EX-99.1
0joqhl
4 Aug 20
Karyopharm Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress
7:13am
8-K
EX-99.1
sarb2cufy
14 Jul 20
Karyopharm Announces Preliminary Unaudited Second Quarter
7:08am
8-K
EX-99.1
h0k1y
22 Jun 20
Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of
4:34pm
8-K
EX-99.1
etwbw rgu8sb
2 Mar 20
Other Events
7:05am
8-K
EX-99.1
14kf0nvbcg
13 Feb 20
Karyopharm Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Company Progress
7:09am
8-K
EX-99.1
fs16q 9n4
13 Jan 20
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Product Sales for XPOVIO® (selinexor) and Provides Commercial Update
7:12am
8-K
EX-99.2
cb54xgx4 r696qzksg
9 Dec 19
Karyopharm Reports New and Updated XPOVIO® (Selinexor) Data in Relapsed or
7:30am
8-K
EX-99.1
x24qrj8c2zt83n2
9 Dec 19
Karyopharm Reports New and Updated XPOVIO® (Selinexor) Data in Relapsed or
7:30am
8-K
EX-99.1
9iq8s
3 Jul 19
Karyopharm Announces FDA Approval of XPOVIOTM(selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
1:10pm
8-K
EX-99.1
aip7v0i68
8 Nov 18
Karyopharm Reports Third Quarter 2018 Financial Results and Highlights Recent Company Progress
7:08am